Kin Meds vs bmiMD
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD opens cheaper — $99/mo against $149, and bmiMD finishes ahead, 9.1 to 6.5. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Kin Meds
$53 off first order, applied automatically at checkout per kinmeds.com/glp1-discount ('Save $53 on first order -Discount applied at checkout')
$53 off first order, auto-applied; discount page quotes starting dose 'as low as $49/week' first month
Entry pricing — likely insured/savings-card tier; cash-pay NovoCare standard pen is $299/mo (oral pill $149)
Entry pricing — likely insured/savings-card tier; cash-pay LillyDirect vials run $299-$449/mo
Matches the LillyDirect $149/mo starter cash price for Foundayo
bmiMD
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
What’s included
Kin Meds
Inclusions not disclosed.
bmiMD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Kin Meds
6.5/10
bmiMD
9.1/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Kin Meds | bmiMD |
|---|---|---|
| Starting Price | $149/mo | ✓$99/mo |
| Features | ✓8 features | 2 features |
| States Available | Not disclosed | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 1 warning | ✓None |
About Kin Meds
Kin Meds starts compounded semaglutide at $199/mo and compounded tirzepatide at $249/mo, and carries brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo. It is LegitScript-verified. Beyond weight loss the account also covers Sermorelin, NAD+, glutathione, TRT, hair, skin and sexual health, so members can run several protocols in one place.
Read our full Kin Meds review →About bmiMD
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Read our full bmiMD review →Pros & Cons
Kin Meds
What we like
- Orforglipron at $149 a month, within the normal band around this register's $149 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
Watch-outs
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
bmiMD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
bmiMD takes it, 9.1 against 6.5, and it is especially strong on starting below a standard dose, with microdose tiers. Kin Meds is no weak second and may fit you better on oral orforglipron alongside the injectables.
Choose Kin Meds if…
You want oral orforglipron alongside the injectables and an opening price near $149 a month.
Choose bmiMD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →Kin Meds vs bmiMD: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Kin Meds and bmiMD head-to-heads in the same category.
- Kin Meds vs Trimi Health
- Kin Meds vs Embody
- Kin Meds vs He & She MD
- bmiMD vs Lean Meds
- bmiMD vs NextMeds
- bmiMD vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.